MX2023001299A - Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. - Google Patents
Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.Info
- Publication number
- MX2023001299A MX2023001299A MX2023001299A MX2023001299A MX2023001299A MX 2023001299 A MX2023001299 A MX 2023001299A MX 2023001299 A MX2023001299 A MX 2023001299A MX 2023001299 A MX2023001299 A MX 2023001299A MX 2023001299 A MX2023001299 A MX 2023001299A
- Authority
- MX
- Mexico
- Prior art keywords
- n3pglu
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 2
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000011419 induction treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un tratamiento de inducción a corto plazo con anticuerpos anti- Aß N3pGlu de una enfermedad caracterizada por la deposición de Aß en el cerebro, que incluye la enfermedad de Alzheimer (AD), el síndrome de Down y la angiopatía amiloide cerebral (CAA). En determinadas modalidades, a los pacientes se les administra una dosis de inducción de 10 a 60 mg/kg de un anticuerpo anti-Aß N3pGlu durante un período de 6 meses o menos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357579P | 2016-07-01 | 2016-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001299A true MX2023001299A (es) | 2023-02-22 |
Family
ID=59295341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016066A MX2018016066A (es) | 2016-07-01 | 2017-06-23 | Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos. |
| MX2023001299A MX2023001299A (es) | 2016-07-01 | 2018-12-18 | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016066A MX2018016066A (es) | 2016-07-01 | 2017-06-23 | Anticuerpos anti- péptido beta amiloide n3pglu y usos de los mismos. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11312763B2 (es) |
| EP (2) | EP3478712B1 (es) |
| JP (4) | JP7165588B2 (es) |
| KR (3) | KR102221402B1 (es) |
| CN (3) | CN114887054A (es) |
| AU (1) | AU2017291414B2 (es) |
| BR (1) | BR112018073843A2 (es) |
| CA (1) | CA3029550C (es) |
| DK (1) | DK3478712T5 (es) |
| EA (1) | EA201892690A1 (es) |
| ES (1) | ES2958508T3 (es) |
| FI (1) | FI3478712T3 (es) |
| HR (1) | HRP20230861T1 (es) |
| HU (1) | HUE062980T2 (es) |
| IL (1) | IL263788B2 (es) |
| LT (1) | LT3478712T (es) |
| MA (1) | MA45543B1 (es) |
| MD (1) | MD3478712T2 (es) |
| MX (2) | MX2018016066A (es) |
| NZ (1) | NZ772768A (es) |
| PL (1) | PL3478712T3 (es) |
| PT (1) | PT3478712T (es) |
| RS (1) | RS64386B1 (es) |
| SG (1) | SG11201810371XA (es) |
| SI (1) | SI3478712T1 (es) |
| TW (2) | TWI798751B (es) |
| UA (2) | UA127101C2 (es) |
| WO (1) | WO2018005282A1 (es) |
| ZA (1) | ZA201807633B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3521308B1 (en) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| CN118924896A (zh) * | 2018-07-24 | 2024-11-12 | 卫材R&D管理有限公司 | 阿尔茨海默病的治疗及预防方法 |
| CN111184725B (zh) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | 一种防治脑梗塞的药物制剂及其制备方法 |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CR20240170A (es) | 2021-10-29 | 2024-05-24 | Lilly Co Eli | Compuestos y métodos dirigidos a la interleucina-34 |
| EP4423129A1 (en) * | 2021-10-29 | 2024-09-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| JP7780010B2 (ja) * | 2021-10-29 | 2025-12-03 | イーライ リリー アンド カンパニー | インターロイキン－３４を標的とする化合物及び方法 |
| US20250296997A1 (en) * | 2021-10-29 | 2025-09-25 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| KR102753583B1 (ko) | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| US20250099434A1 (en) * | 2022-01-26 | 2025-03-27 | T3D Therapeutics, Inc. | Methods of treating amyloid related brain disorders using novel compounds and antibodies |
| KR20240145486A (ko) * | 2022-02-03 | 2024-10-07 | 일라이 릴리 앤드 캄파니 | 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화 |
| WO2025106313A1 (en) | 2023-11-14 | 2025-05-22 | Eli Lilly And Company | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| CN101351476B (zh) | 2005-12-12 | 2013-04-03 | 豪夫迈·罗氏有限公司 | 抗体可变区的糖基化 |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| AU2008206555B2 (en) | 2007-01-18 | 2013-07-04 | Eli Lilly And Company | Pegylated Abeta Fab |
| ES2498040T3 (es) * | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| KR20110036809A (ko) | 2008-06-12 | 2011-04-11 | 아피리스 아게 | 파킨슨병과 관련된 증상을 치료하기 위한 화합물 |
| US20110182809A1 (en) | 2008-07-09 | 2011-07-28 | University Of Zurich | Method of Promoting Neurogenesis |
| JP5828762B2 (ja) | 2008-07-21 | 2015-12-09 | プロビオドルグ エージー | 診断用抗体アッセイ |
| CN101397539B (zh) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | 组织工程组织仿生培养的模拟人体生理应力的施力装置 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2576617B1 (en) | 2010-06-04 | 2016-04-27 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS |
| PL2603523T3 (pl) * | 2010-08-12 | 2016-07-29 | Lilly Co Eli | Przeciwciała przeciwko peptydowi amyloidu beta N3pGlu i ich zastosowania |
| WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| WO2014089500A1 (en) | 2012-12-07 | 2014-06-12 | Biogen Idec International Neuroscience Gmbh | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| MX388168B (es) | 2014-02-08 | 2025-03-19 | Genentech Inc | Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer. |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| JP6201928B2 (ja) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | 車両制御装置 |
| TWI570127B (zh) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| WO2016053767A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Novel crystalline forms of a bace inhibitor, compositions, and their use |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2017
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-23 DK DK17736841.2T patent/DK3478712T5/da active
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 IL IL263788A patent/IL263788B2/en unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en not_active Ceased
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt unknown
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active Active
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 NZ NZ772768A patent/NZ772768A/en unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Withdrawn
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 UA UAA202202998A patent/UA129392C2/uk unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active Ceased
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
-
2020
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001299A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| ZA201803396B (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| MX2025010483A (es) | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| EA201990559A1 (ru) | Комбинированная терапия | |
| IL288636A (en) | Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab | |
| IL288600A (en) | Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab | |
| EA201992284A1 (ru) | Композиции и способы лечения синуклеинопатий | |
| EA201892739A1 (ru) | Способы лечения болезни альцгеймера | |
| GB201819758D0 (en) | Medicine for the treatment of Alzheimer's disease | |
| NZ772814B2 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| NZ772814A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| TN2019000238A1 (en) | Methods for treating complement-mediated diseases and disorders | |
| HK1236975A1 (en) | Method for treating alzheimer's disease | |
| UA93956U (uk) | Спосіб лікування хворих на туберкульоз легень |